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EML4-ALK lung cancer accounts for approximately 3–7% of non-small-cell lung
cancer cases. To investigate the molecular mechanism underlying tumor progres-
sion and targeted drug sensitivity ⁄ resistance in EML4-ALK lung cancer, clinically
relevant animal models are indispensable. In this study, we found that the lung
adenocarcinoma cell line A925L expresses an EML4-ALK gene fusion (variant 5a,
E2:A20) and is sensitive to the ALK inhibitors crizotinib and alectinib. We further
established highly tumorigenic A925LPE3 cells, which also have the EML4-ALK
gene fusion (variant 5a) and are sensitive to ALK inhibitors. By using A925LPE3
cells with luciferase gene transfection, we established in vivo imaging models for
pleural carcinomatosis, bone metastasis, and brain metastasis, all of which are
significant clinical concerns of advanced EML4-ALK lung cancer. Interestingly, criz-
otinib caused tumors to shrink in the pleural carcinomatosis model, but not in
bone and brain metastasis models, whereas alectinib showed remarkable efficacy
in all three models, indicative of the clinical efficacy of these ALK inhibitors. Our
in vivo imaging models of multiple organ sites may provide useful resources to
analyze further the pathogenesis of EML4-ALK lung cancer and its response and
resistance to ALK inhibitors in various organ microenvironments.
A LK rearrangement, most commonly EML4-ALK, isdetected in approximately 3–7% of unselected NSCLC
cases.(1,2) EML4-ALK NSCLC is more frequently observed in
patients with adenocarcinoma than in those with other dis-
eases, in young adults than in older patients, and in non- or
light smokers (<15 packs ⁄year) than in heavier smokers.(3)
EML4-ALK and other driver gene alterations such as EGFR
mutations and KRAS mutations are almost mutually exclu-
sive.(1) Crizotinib, an ALK TKI, shows dramatic clinical effi-
cacy, with a response rate of approximately 60–80%, and a
progression-free survival of approximately 9–10 months in
ALK-rearranged NSCLC patients.(4,5) However, almost all
patients who strongly responded to crizotinib acquired resis-
tance over time.(6) Recently, new generation ALK-TKIs such
as alectinib(7) and ceritinib(8) have been approved for treatment
of ALK-rearranged NSCLC patients, and it is now clear that
resistance may also develop against this class of inhibitors.
Thus, further research into the molecular pathogenesis of
EML4-ALK lung cancer and the mechanism of ALK inhibitor
resistance is necessary to further improve the prognosis of this
disease.
For such studies, EML4-ALK lung cancer cell lines are
essential resources. However, the number of EML4-ALK lung
cancer cell lines is still very limited. In addition, while in vivo
imaging is a method for studying mechanisms of cancer pro-
gression and the efficacy of targeted drugs,(9) clinically rele-
vant in vivo imaging models for EML4-ALK lung cancer have
not been established. In this study, we identified a novel
human lung adenocarcinoma cell line, A925L, that harbors an
EML4-ALK gene fusion (variant 5a, E2:A20, a rare isoform).
We established highly tumorigenic A925LPE3 cells from the
A925L cells after in vivo selection cycles and further devel-
oped in vivo imaging models for pleural carcinomatosis, bone
metastasis (bone lesion), and brain metastasis (brain lesion).
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Materials and Methods
Cell cultures and reagents. A human lung adenocarcinoma
cell line, A925L, established from a surgical specimen
obtained from a Japanese male patient (T2N2M0, stage IIIA),
was maintained in RPMI-1640 medium, supplemented with
10% FBS, penicillin (100 U ⁄mL), and streptomycin (10 lg
⁄mL), in a humidified CO2 incubator at 37°C. The character-
istics of this cell line are documented in a previous report.(10)
The H2228 human lung adenocarcinoma cell line, with the
EML4-ALK fusion protein variant 3 (E6;A20) were pur-
chased from the ATCC (Manassas, VA, USA). The H3122
human lung adenocarcinoma cell line, with the EML4-ALK
fusion protein variant 1 (E13;A20), was kindly provided by
Dr. Jeffrey A. Engelman of the Massachusetts General Hospi-
tal Cancer Center (Boston, MA, USA).(11) PC-9 cells, an
EGFR mutant human lung adenocarcinoma cell line, were
obtained from Immunobiological Laboratories Co. (Fujioka,
JAPAN), Ltd. All cells were passaged for <3 months before
renewal from frozen, early-passage stocks. Cells were regu-
larly screened for mycoplasma by using MycoAlert Myco-
plasma Detection Kits (Lonza, Rockland, ME, USA).
Crizotinib and alectinib (Fig. S1) were obtained from Selleck
Chemicals (Houston, TX, USA).
Tumor cell inoculation in SCID mice. We used 5-week-old
female SCID mice (Clea, Tokyo, Japan) for the study. For the
pleural carcinomatosis model,(12) the skin and subcutaneous
tissue on the right side of the chest were cut and the parietal
pleura was exposed. Tumor cells (1 9 106 ⁄100 lL) were then
injected into the right thoracic cavity through the parietal
pleura by using a 27-G needle. Subsequently, the incisions
were sutured to close the wound.
For the bone metastasis model,(13) the knee joint was steril-
ized with 70% ethanol, and a percutaneous intraosseal injec-
tion was carried out by drilling a 27-G needle into the tibia,
immediately proximal to the tuberositas tibiae. After penetra-
tion of the cortical bone, the needle was further inserted into
the shaft of the tibia and was used to deposit 4 lL tumor cell
suspension (4 9 105 ⁄4 lL) in the cortex.
For the brain metastasis model,(14) the scalp was sterilized
with 70% ethanol, and a small hole was bored into the skull,
0.5 mm anterior and 3.0 mm lateral to the bregma, using a
dental drill. Cell suspensions (1.5 9 105 ⁄1.5 lL) were injected
into the right striatum, 3 mm below the surface of the brain,
using a 10-lL Hamilton syringe with a 26-G needle. The scalp
was closed using an Autoclip Applier, which were purchased
from the BD (Franklin Lakes, NJ, USA).
After 7–11 days, the mice were randomized and treated orally
with or without crizotinib or alectinib. The size of s.c. tumors
and mouse body weights were measured twice per week, and
tumor volume was calculated in mm3, as width2 9 length ⁄2.
This study was carried out in strict accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory
Animals of the Ministry of Education, Culture, Sports, Science
and Technology, Japan. The protocol was approved by the Com-
mittee on the Ethics of Experimental Animals, and the
Advanced Science Research Center, Kanazawa University,
Kanazawa, Japan (approval no. AP-132618). All surgeries were
carried out under sodium pentobarbital anesthesia, and efforts





Fig. 1. Establishment of highly tumorigenic EML4-
ALK non-small-cell lung cancer cell line. (a) A925L is
the parental cell line. A925LPE3 cells were
established after three cycles of in vivo selection.
A925LPE3 ⁄ Eluc cells were established after
transfection of Eluc-EGFP gene into A925LPE3 cells.
(b, c) Tumor cells were inoculated into the right
thoracic cavity of SCID mice. A925L cells inoculated
into the thoracic cavity rarely produced pleural
effusion or thoracic tumors, whereas A925LPE3 cells
developed pleural effusion in all recipient mice.
Arrow heads, pleural effusion; H, heart; L, liver. (d)
Tumor cells were detected in the pleural effusion
produced by A925LPE3 cells. (e, f) A925LPE3 cells
produced disseminated small lesions on the lung.
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Multiplex RT-PCR analysis of EML4-ALK. RNA was extracted
using an automated BioRobot EZ1 workstation (Qiagen:
Tokyo, JAPAN). The isolated RNA was subjected to RT with
a ReverTra Ace qPCR RT kit (Toyobo: Osaka, JAPAN), and
the resulting cDNA was subjected to PCR for 50 cycles of
94°C for 15 s, 60°C for 30 s, and 72°C for 1 min with Amp-
liTaq Gold DNA polymerase (Applied Biosystems: Carlsbad,
CA, USA) and 2 lmol ⁄L each primer listed in Table S1.(15)
The PCR products were subjected to Sanger sequencing to
confirm the presence of EML4-ALK.
Fluorescence in situ hybridization. The FISH technique, used
to detect ALK fusion genes, was carried out as reported previ-
ously(16) using the Vysis ALK break-apart FISH probe, accord-
ing to the hybridization and scoring protocol in the package
insert (Abbott Molecular, Des Plaines, IL, USA).
Cell viability assay. Cell viability was measured by the MTT
dye reduction method. Tumor cells, plated at a density of
2 9 103 ⁄100 lL RPMI-1640 plus 10% FBS per well in
96-well plates, were incubated for 24 h. Crizotinib or alectinib
were then added to each well, and incubation was continued
for another 72 h. Cell growth was measured with MTT solu-
tion (2 mg ⁄mL; Sigma, St. Louis, MO, USA), as described.(17)
Antibodies and Western blot analysis. Protein aliquots of
25 lg each were used for Western blotting. The primary anti-
bodies used were anti-ALK (C26G7), anti-phospho-ALK
(Tyr1604), anti-STAT3 (79D7), antiphospho-STAT3 (Y705),
Akt, and p-Akt (S473) (all Cell Signaling Technology, Bev-
erly, MA, USA), as well as human ⁄mouse ⁄ rat ERK1 ⁄ERK2
and p-ERK1 ⁄ERK2 (T202 ⁄Y204) (R&D Systems, Minneapo-
lis, MN, USA). The membranes treated with the primary anti-
bodies were incubated for 1 h at room temperature with
species-specific HRP-conjugated secondary antibodies. Immu-
noreactive bands were visualized with SuperSignal West Dura
Extended Duration Substrate, an enhanced chemiluminescent
substrate (Pierce Biotechnology, Rockford, IL, USA). The data
presented are representative of three independent experiments.
Histological analyses of tumors. Proliferating cells were
detected by incubating tissue sections with Ki-67 antibody
(Clone MIB-1; Dako, Glostrup, Denmark). Antigen was
retrieved by microwaving tissue sections in 10 mM citrate buf-
fer (pH 6.0). After incubation with secondary antibody and
treatment with the Vectastain ABC Kit (Vector Laboratories,
Burlingame, CA, USA), peroxidase activity was visualized
using the DAB reaction. The sections were counterstained with
hematoxylin.
EGFP-Eluc gene transfection. The cDNA of EGFP from
pIRES-EGFP Vector (Invitrogen, Carlsbad, CA, USA) and




Fig. 2. A925L and 925LPE3 cells harbor the EML4-ALK fusion gene and are sensitive to anaplastic lymphoma kinase (ALK)–tyrosine kinase inhibi-
tors. (a) Multiplex RT-PCR for EML4-ALK was carried out. V, variant. (b) Break-apart FISH revealed that A925L and A925LPE3 cells have an ALK
fusion gene. (c) Tumor cells were treated with crizotinib or alectinib for 72 h. The cell viability was determined by MTT assay. (d) Tumor cells
were treated with crizotinib (1 lM) or alectinib (1 lM) for 1 h. The cell lysates were harvested and proteins and phosphorylation (P-) statuses
were examined by Western blot analysis. STAT3, signal transducer and activator of transcription 3.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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Toyobo) were cloned into MaRXIVf Puro retroviral vector
(Fig. S2). All cDNA were sequenced. Transfection was carried
out using Lipofectamine LTX and PLUS Reagent (Invitrogen)
and retroviral infection was carried out using Retrovirus Pack-
aging Kit Ampho (Takara: Otsu, JAPAN) according to the
manufacturer’s instructions. The cells were then selected in
puromycin.
Luciferase expression analysis and radiographic analysis by IVIS
imaging system. Two to three weeks after inoculation, the quan-
tity of tumors and the quality of bones were tracked in live mice
by repeated non-invasive optical imaging of tumor-specific
luciferase activity using the IVIS Lumina XR Imaging System
(PerkinElmer, Alameda, CA, USA). Twenty minutes after lucif-
erase substrate luciferin (150 mg ⁄kg) i.p. injection, mice were
photographed under bright-field illumination and images were
overlaid with luminescence data gathered over the maximum
exposure period (5–30 s) while anesthetized by 2% isoflurane.
The intensity of the bioluminescence signal was analyzed using
Living Image 4.0 (PerkinElmer) by serially quantifying peak
photon flux at the selected region of interest covering the tumor
and corrected for total area of region of interest and time lapse,
during which the bioluminescence signals were picked by the
charge-coupled device camera and expressed as photons ⁄ s
⁄ cm2 ⁄ sr (sr:steradian). At the same time, the X-ray was con-
verted to visible light by a scintillator, and the image captured
on a charge-coupled device by the IVIS Lumina XR Imaging
System.
Results
A925LPE3 cells have high potential to produce thoracic tumors
and pleural effusion in SCID mice. Almost all EML4-ALK lung
cancers are adenocarcinomas, which are often associated with
pleural carcinomatosis in the advanced stages. Pleural carcino-
matosis is, sometimes, the first sign of progression observed dur-
ing the onset of resistance to crizotinib treatment.(4) In fact, Choi
et al.(18) discovered a resistant ALK mutation by using pleural
effusion cell DNA obtained from an EML4-ALK lung cancer
patient who acquired crizotinib resistance. We inoculated
A925L cells into the thoracic cavity of SCID mice and found
that two out of eight mice developed pleural effusion-containing
tumor cells (Fig. 1). We harvested the pleural effusion-contain-
ing tumor cells and cultured them in vitro. These cells were then
inoculated into the thoracic cavity of SCID mice. After three
cycles, we established A925LPE3 cells. Compared to the paren-
tal A925L cells, A925LPE3 cells display a higher potential to
produce pleural effusion in SCID mice (Fig. 1).
A925L and A925LPE3 harbor an EML4-ALK gene fusion and are
sensitive to ALK-TKIs. The RT-PCR analysis revealed that both
the parental A925L cells and the derivative A925LPE3 cells
expressed an EML4-ALK gene fusion product (variant 5a, E2:
A20) (Fig. 2a), as confirmed against the sequence of EML4-
ALK (Fig. S3). Break-apart FISH also indicated the presence
of ALK fusion genes in both A925L and A925LPE3 cells
(Fig. 2b). In addition, both the parental and derivative cell
lines displayed a similar sensitivity to ALK-TKIs such as criz-
otinib and alectinib. A925L and A925LPE3 cells showed an
intermediate sensitivity to crizotinib and alectinib compared
with that shown by other EML4-ALK lung cancer cell lines
such as H3122 (variant 1, E13:A20) and H2228 (variant
3a+3b, E6:A20), which are highly and slightly sensitive to
ALK-TKIs, respectively (Fig. 2c, Table S2). We verified that
the observed sensitivity of A925L and A925LPE3 cells to criz-
otinib or alectinib treatment correlated with inhibition of both
phosphorylation of ALK and phosphorylation of downstream
molecules such as STAT3, AKT, and ERK (Fig. 2d).
Subcutaneously inoculated A925L cells are sensitive to ALK-
TKIs. We next examined the effect of ALK-TKIs on s.c.
(a) (b)
(c) (d)
Fig. 3. Crizotinib and alectinib show antitumor
activity on s.c. tumors produced by A925L cells. (a)
A925L (1 9 106) cells were inoculated s.c. into SCID
mice. After tumor volumes reached 200 mm3, daily
oral treatment with crizotinib or alectinib was
initiated. (b) Tumors were harvested after 18 days
from treatment initiation, and the lysates were
evaluated for the expression and phosphorylation
(p-) of anaplastic lymphoma kinase (ALK) by
Western blot analysis after immunoprecipitation for
ALK protein. (c) Tumors harvested were evaluated
for proliferating tumor cells by
immunohistochemical staining for Ki-67. (d)
Proliferating tumors cells were quantified.
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tumors produced by A925L cells. Compared to treatment with
control, treatment with 25 mg ⁄kg crizotinib retarded tumor
growth; however, 50 mg ⁄ kg crizotinib was required to induce
tumor shrinkage. Under the same experimental conditions,
treatment with 25 mg ⁄kg alectinib caused remarkable tumor
shrinkage, and the tumors disappear after only 7 days of treat-
ment (Fig. 3a).
Western blot analysis with in vivo treated tumors showed
that crizotinib treatment suppressed ALK phosphorylation and
that alectinib treatment, more impressively, inhibited it
(Fig. 3b). In association with the degree of ALK phosphoryla-
tion inhibition, proliferation of tumors cells was also inhibited
by treatment with either crizotinib or alectinib (Fig. 3c,d).
These results indicate that parental A925L cells were sensitive
to ALK-TKIs when evaluated in a s.c. tumor model.
Establishment of A925LPE3 ⁄ Eluc cells for in vivo imaging. In
vivo imaging is a powerful tool for evaluating the degree of
tumor progression and the efficacy of treatment. To this end,
we transfected the Eluc/EGFP gene (Fig. S2) into highly
tumorigenic A925LPE3 cells and established A925LPE3 ⁄Eluc
cells. A925LPE3 ⁄Eluc cells constitutively expressed green flu-
orescence signal (Fig. S4a); luminescence signal was detected
after the addition of luciferin (Fig. S4b). In the s.c. model,
tumor volume and the luminescence shown by A925LPE3
⁄Eluc cells increased in a time-dependent manner, indicating
that luminescence was proportional to the tumor volume pro-
duced by A925LPE3 ⁄Eluc cells (Fig. S5).
In vivo imaging model for pleural carcinomatosis. To create a
pleural carcinomatosis model, A925LPE3 ⁄Eluc cells were
inoculated into the thoracic cavities of SCID mice. We were
able to detect luminescence in the chest 12 days after tumor
cell inoculation, and the luminescence increased in a time-
dependent manner, reflecting tumor progression (Fig. 4). The
mice became moribund between days 28 and 35. Daily oral
treatment with 50 mg ⁄kg crizotinib or 25 mg ⁄kg alectinib,
starting on day 12, decreased luminescence until it almost dis-
appeared on day 28, indicating the high efficacies of crizotinib
and alectinib in the pleural carcinomatosis model developed
using A925LPE3 ⁄Eluc cells.
In vivo imaging model for bone metastasis. To create a bone
metastasis model, A925LPE3 ⁄Eluc cells were inoculated into
the tibias of SCID mice. We were able to detect luminescence
in tibias 10 days after tumor cell inoculation, and the lumines-
cence increased in a time-dependent manner, reflecting tumor
progression in the bone (Fig. 5). X-ray photographs revealed
that A925LPE3 ⁄Eluc cells produced osteolytic lesion by day
28, and histological examinations confirmed osteolytic
changes in tibias harboring tumor cells (Fig. 5a). Daily oral
treatment with 50 mg ⁄kg crizotinib, starting on day 10, pre-
vented a further increase in luminescence (Fig. 5b) as well as
osteolytic changes (Fig. 5c), but did not reduce the lumines-
cence below the starting point. However, daily oral treatment
with 25 mg ⁄kg alectinib, starting on day 10, significantly
decreased luminescence, indicating that alectinib was highly
efficacious against bone lesions produced by A925LPE3 ⁄Eluc
cells.
In vivo imaging model for brain metastasis. To create a brain
metastasis model, A925LPE3 ⁄Eluc cells were inoculated into
the cerebra of SCID mice, and histological examinations con-
firmed the presence of tumors in the cerebra (Fig. 6a,b). Fur-
thermore, luminescence was detected in the brain 11 days
after tumor cell inoculation, and the luminescence increased in
a time-dependent manner, reflecting tumor progression in the
cranial space (Fig. 6c). The mice became moribund between
days 26 and 30. Daily oral treatment with 50 mg ⁄kg crizoti-
nib, starting on day 11, delayed the increase of luminescence,
but did not decrease it, whereas daily oral treatment with
25 mg ⁄kg alectinib, starting on day 11, significantly decreased
luminescence (Fig 6c,d), indicating that alectinib was highly
efficacious against brain lesions produced by A925LPE3 ⁄Eluc
cells.
Discussion
The EML4-ALK fusion gene accounts for more than 90% of
ALK fusion genes. However, only a limited number of NSCLC
cell lines that contain EML4-ALK fusion, such as H3122 and
H2228, are available.(19,20) In the present study, we identified
that human lung adenocarcinoma cell line A925L had EML4-
ALK variant 5 (E2:A20). At least 14 isoforms of EML4-ALK
have been reported so far,(15) and variants 1 and 3 account for
90% of EML4-ALK variants.(6) Ethnicity is partly responsible
for these high incidence rates, with EML4-ALK variants 1 and
3 being dominant in Caucasians(21) and East Asians,(22) respec-
tively. It was also reported that different EML4-ALK variants
(a)
(b)
Fig. 4. Pleural carcinomatosis model of A925LPE3 ⁄ Eluc cells and effi-
cacy of anaplastic lymphoma kinase–tyrosine kinase inhibitors. (a)
A925LPE3 ⁄ Eluc cells were inoculated into the thoracic cavity of SCID
mice. Mice were treated with control (n = 5), 50 mg ⁄ kg crizotinib
(n = 5), or 25 mg ⁄ kg alectinib (n = 5). Treatment was given daily on
days 12–28. Luminescence was evaluated twice per week. Bars indicate
standard error (p ⁄ s: photons ⁄ second). (b) Appearance of representative
mice is shown.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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show differential sensitivity to ALK-TKIs;(23) variant 2 is the
most sensitive to ALK-TKIs, followed by variants 1 and 3b,
whereas variant 3a is the most resistant. Variant 5 is a rare iso-
form (accounting for only 1.5%),(21) and the sensitivity of vari-
ant 5 to ALK-TKIs was largely unknown. We observed that
A925L and A925LPE3 cells with EML4-ALK variant 5a
showed intermediate sensitivity to crizotinib and alectinib
compared to that observed with H3122 (variant 1) and H2228
(variant 3a+3b) cells, thereby proving the usefulness of A925L
and A925LPE3 cells as tools for the molecular and biological
analysis of EML4-ALK variant 5.
Several xenograft models of human lung cancer cell lines
and immunodeficient mice have been reported, including the
s.c. inoculation model,(24) the orthotopic implantation
model,(25) and the experimental metastasis model.(26) Each
model has advantages and disadvantages. The s.c. inoculation
model is technically easy to perform and allows for a wide
variety of human lung cancer cell lines; however, tumors grow
in an ectopic, clinically less relevant, microenvironment. The
orthotopic implantation model allows tumors to grow in an
orthotopic, clinically relevant microenvironment.(27) However,
human lung cancer cell lines adaptive to this model are lim-
ited, and clinically relevant metastasis to distant organs such
as the brain and bone almost never occurs. Finally, the experi-
mental metastasis model with a tail vein injection is techni-
cally easy to carry out, and lung metastasis occurs frequently,
if adequate cell lines are used. In fact, A925LPE3 cells con-




Fig. 5. Bone metastasis model of A925LPE3 ⁄ Eluc cells and efficacy of anaplastic lymphoma kinase–tyrosine kinase inhibitors. (a) H&E staining of
bone lesions. Arrow head indicates osteolytic change. (b) A925LPE3 ⁄ Eluc cells were inoculated into the tibia of SCID mice. Mice were treated
orally with control (n = 5), 50 mg ⁄ kg crizotinib (n = 5), or 25 mg ⁄ kg alectinib (n = 5). Treatment was given daily on days 10–28. Luminescence
was evaluated twice per week. Bars indicate standard error. (c) Appearance of representative mice is shown.
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rarely produce metastasis into the bone or brain after i.v. or
intracardiac injection (Table S3). Once again, however, metas-
tases to the brain or bone, which are serious clinical concerns
of advanced lung cancer patients, are rarely witnessed. When
we used the well-characterized EML4-ALK lung cancer cell
lines H3122 and H2228, both of H3122 and H2228 cell lines
produced tumors after inoculation into the skin, but not tho-
racic cavity, bone, or brain of SCID mice (Table S4). In
addition, compared with H3122 and A925L cells, H2228 cells
are much less sensitive to ALK-TKIs, rendering these cells
inadequate for investigation of acquired ALK-TKI resistance.
As documented in this study, A925LPE3 cells are more
tumorigenic than A925L, H3122, or H2228 cells, and they
constantly produce tumor lesions after inoculation into the
thoracic cavity, brain, and bone. Although A925LPE3 cells
in these models skipped the invasion of the pleura and early
metastatic cascades (from the steps of growth in the primary
lesion to extravasation into the metastatic lesion), these
models can be powerful tools for elucidating the mecha-
nisms underlying tumor progression and the response and
resistance to ALK-TKIs in the thoracic cavity, brain, and
bone.
Molecular targeted drugs sometimes show heterogeneous
efficacy among lesions in different organs. In the case of
ALK-TKIs, crizotinib is less effective on brain lesions com-
pared with lesions in other locations. In fact, CNS lesions,
including brain metastases, frequently progress during crizoti-
nib treatment,(4) leading some to refer to the CNS as a sanc-
tuary site for crizotinib treatment.(28) On the contrary, a
recent study reported that alectinib has high efficacy on CNS
lesions that became refractory to crizotinib.(29) Our data are





Fig. 6. Brain metastasis model of A925LPE3 ⁄ Eluc
cells and efficacy of anaplastic lymphoma kinase–
tyrosine kinase inhibitors. A925LPE3 ⁄ Eluc cells were
inoculated into the cerebrum of SCID mice. (a)
Macroscopic appearance of brain tumors. (b)
Microscopic appearance of brain lesions (9200). (c)
Mice were treated orally with control (n = 5),
50 mg ⁄ kg crizotinib (n = 5), or 25 mg ⁄ kg alectinib
(n = 5). Treatment was given daily on days 11–40.
Luminescence was evaluated twice per week. Bars
indicate standard error. (d) Appearance of
representative mice is shown.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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as effective in our brain metastasis model as alectinib, which
was highly effective in the same model. A transgenic mouse
model of EML4-ALK is a powerful tool for the analysis of
NSCLC tumorigenesis and tumor progression, as well as the
efficacy of ALK-TKIs in the lung.(30) However, as tumors
are selectively developed in the lung, it is impossible to
assess the efficacy of ALK-TKIs against lesions in locations
other than lung in the transgenic mouse model. Therefore,
our model is complementary to other models, such as the
s.c. model and transgenic mouse model, in that it will allow
researchers to evaluate the heterogeneous efficacy of ALK-
TKIs on multiple organ lesions and contribute to the devel-
opment of novel therapies for EML4-ALK lung cancer. We
are now intensively undertaking such experiments by using
these models.
In summary, we identified A925L cells as an EML4-ALK
variant 5 lung cancer cell line. Moreover, we established
A925LPE3 cells with high tumorigenicity in SCID mice after
in vivo selection cycles and further developed in vivo imaging
models for pleural carcinomatosis, brain metastasis (brain
lesion), and bone metastasis (bone lesion). These models may
be useful resources for analyzing the pathogenesis of EML4-
ALK variant 5, elucidating the molecular mechanisms underly-
ing response and resistance to ALK-TKIs, and developing
novel therapies against EML4-ALK lung cancer.
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